Roivant Sciences (ROIV) to Release Quarterly Earnings on Friday

Roivant Sciences (NASDAQ:ROIV) is projected to issue its Q3 2026 results before the market opens on Friday, February 6th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $6.1390 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Friday, February 6, 2026 at 8:00 AM ET.

Roivant Sciences Price Performance

Shares of ROIV opened at $21.65 on Thursday. The firm has a market capitalization of $15.06 billion, a price-to-earnings ratio of -38.66 and a beta of 1.22. Roivant Sciences has a 1-year low of $8.73 and a 1-year high of $23.91. The company has a 50-day moving average of $21.96 and a 200 day moving average of $17.64.

Insider Activity at Roivant Sciences

In other news, CFO Richard Pulik sold 406,731 shares of the firm’s stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a total value of $9,122,976.33. Following the sale, the chief financial officer directly owned 239,413 shares in the company, valued at approximately $5,370,033.59. This trade represents a 62.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $21.92, for a total transaction of $4,384,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,654,597 shares in the company, valued at approximately $36,268,766.24. The trade was a 10.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 12,332,392 shares of company stock valued at $266,393,645 over the last 90 days. Company insiders own 10.80% of the company’s stock.

Institutional Trading of Roivant Sciences

Institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in shares of Roivant Sciences during the third quarter worth $188,000. State of Wyoming acquired a new position in shares of Roivant Sciences in the 2nd quarter valued at $159,000. Vident Advisory LLC raised its stake in Roivant Sciences by 22.7% in the 2nd quarter. Vident Advisory LLC now owns 26,292 shares of the company’s stock worth $296,000 after acquiring an additional 4,856 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Roivant Sciences during the 2nd quarter worth about $248,000. Finally, Jump Financial LLC grew its stake in Roivant Sciences by 24.2% during the 2nd quarter. Jump Financial LLC now owns 18,592 shares of the company’s stock valued at $210,000 after purchasing an additional 3,622 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Leerink Partners lifted their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Citigroup lifted their target price on Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. The Goldman Sachs Group raised their price target on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Roivant Sciences in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Roivant Sciences presently has an average rating of “Moderate Buy” and an average price target of $25.19.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.